Buchumschlag

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Maryam Irshad, Shahzeen Irshad
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
von: Lingna Ye, et al.
Veröffentlicht: (2025)

Letter: Optimising Targeted Next‐Generation Sequencing for Intestinal Tuberculosis Diagnosis—Methodological Considerations
von: Haleema Rahman
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
von: Kuan‐Ju Lin, et al.
Veröffentlicht: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
von: Moeko Komatsu, et al.
Veröffentlicht: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
von: Kacie H. Denton, et al.
Veröffentlicht: (2026)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
von: Matthias Kelm, et al.
Veröffentlicht: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
von: Dingsheng Liu, et al.
Veröffentlicht: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
von: Jiacheng Li
Veröffentlicht: (2026)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
von: Maryam Alahmad, et al.
Veröffentlicht: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
von: Nathan Grellier, et al.
Veröffentlicht: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
von: Jeffrey D. McCurdy, et al.
Veröffentlicht: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Editorial: Upadacitinib in Perianal Crohn's Disease
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Editorial: “Striding” Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease
von: Rohita Reji, et al.
Veröffentlicht: (2026)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
von: Emmanuel Pio Pastore
Veröffentlicht: (2025)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
von: Jannis Kountouras, et al.
Veröffentlicht: (2025)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
von: Weilun Gao, et al.
Veröffentlicht: (2024)

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study
von: Dhruv Ahuja, et al.
Veröffentlicht: (2025)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
von: Abhirup Chatterjee, et al.
Veröffentlicht: (2024)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Antoine Meyer, et al.
Veröffentlicht: (2025)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
von: Péter Bacsur, et al.
Veröffentlicht: (2024)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
von: Vincenzo Stranges, et al.
Veröffentlicht: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
von: Tim Eglinton
Veröffentlicht: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
von: Shlomi Cohen, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
von: C. Ramos‐Belinchon, et al.
Veröffentlicht: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
von: Christophe Corpechot
Veröffentlicht: (2026)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
von: Marco Mendolaro, et al.
Veröffentlicht: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2024)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
von: Nicolas Richard, et al.
Veröffentlicht: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
von: Nicolas Richard, et al.
Veröffentlicht: (2026)

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
von: Runqi Wang, et al.
Veröffentlicht: (2026)